Development of the multi-tyrosine kinase inhibitor TKI258 for patients with metastatic renal cell carcinoma progressing on an mTOR-inhibitor- preliminary results of a phase I/II trial
Dokumenttyp:
Meeting Abstract
Autor(en):
Gschwend, J; Grunwald, V; Pande, A; Albrecht, M; Anak, O; Escudier, B